Your browser doesn't support javascript.
loading
Novel Use of Calcimimetic Activity to Diagnose Primary Hyperparathyroidism in a Patient With Persistently Low-Normal Parathyroid Hormone Level.
Bandaru, Sindhura; Manthri, Sukesh; Nallala, Deepika; Mamillapalli, Chaitanya K; Jakoby, Michael G.
Afiliação
  • Bandaru S; Internal Medicine, Southern Illinois University School of Medicine, Springfield, USA.
  • Manthri S; Oncology, East Tennessee State University, Johnson City, USA.
  • Nallala D; Endocrinology, Tower Health Medical Group, Wyomissing, USA.
  • Mamillapalli CK; Endocrinology, Springfield Clinic, Springfield, USA.
  • Jakoby MG; Endocrinology, Southern Illinois University School of Medicine, Springfield, USA.
Cureus ; 12(7): e9360, 2020 Jul 23.
Article em En | MEDLINE | ID: mdl-32850231
Primary hyperparathyroidism (PHPT) is the most common etiology of hypercalcemia in the ambulatory setting and usually presents with an intact parathyroid hormone (PTH) level that is elevated or inappropriately near the upper limit of the laboratory reference range. However, PHPT with low-normal PTH level is reported in the peer-reviewed literature, and this atypical presentation may delay diagnosis of PHPT. We present a case of PHPT with persistently low-normal PTH level in which the PTH dependence of hypercalcemia was demonstrated by the response to treatment with the calcimimetic agent cinacalcet.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article